Dupilumab had a fivefold improvement in sustained disease remission in bullous pemphigoid compared with placebo, along with a significant reduction in oral corticosteroid use.

Abrocitinib was efficacious and safe in patients with atopic dermatitis who did and who did not respond to prior treatment with dupilumab.

Dupilumab rapidly treated and maintained improvements in lichenification, a type of skin thickening from repetitive ...

Some patients with psoriasis may have a super response to guselkumab, but questions remain regarding the generalizability of treatment strategies.

The Phase I trial will recruit approximately 98 healthy volunteers and adults living with atopic dermatitis at a single site ...

Dupilumab and tralokinumab treat atopic dermatitis ... Most people can treat their AD with prevention, topical treatments, UV therapy, and by maintaining skin care. Doctors typically wait to ...

"These cytokines appeared to be the key cytokines in defining the disease." When the patient was treated with a dual therapy of two monoclonal antibodies, dupilumab and secukinumab, his symptoms ...

Across six asthma biologics, adherence differed by the therapy given and was often low or irregular based on three adherence measures, according to a presentation here.This cross-sectional cohort ...

Learn how targeted therapy and advanced blood analysis transformed treatment for erthyroderma, a rare inflammatory skin ...

BLA accepted for review Dupilumab (Regeneron and Sanofi ... sNDA accepted AVB-114 (Avobis Bio) Stem cell therapy Treatment of perianal fistulas in patients with Crohn disease.

Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in ...